DIAGNOS Provides Timelines on Cardiovascular Disease (CVD) Prevention Test Development and Commercialization Plans
Cardiovascular Artery Disease (CAD) prevention score development six to twelve months ahead of schedule; commercial launch in
first half of 2018
BROSSARD, QUEBEC--(Marketwired - Sept. 19, 2017) - DIAGNOS Inc. ("DIAGNOS" or "the Corporation") (TSX
VENTURE:ADK)(OTCQB:DGNOF), a leader in early detection of critical health issues through the use of its FL
AI RE platform based on Artificial Intelligence ( AI ), announces
today a development of new cardiovascular risk score, that will enable the early detection of this critical disease by its CARA
platform.
The calibration of our application will be done simultaneously in 4 countries with a minimum of 1,000 in each country with the
support of 22 cardiologists. This will enable us to insure the sustainability of our solution worldwide. The partners that will
be collaborating with DIAGNOS are in Algeria, Canada, Mexico and United States.
"We're at the final development stage and ready to evaluate the effectiveness of our automatic grading for the new risk score
test CARA Cardio. Continually, we hear from physicians and health insurers that our screening tests are very much needed to
detect at early stage the cardiovascular anomalies. Our preventive cardiovascular risk score test will be used to
prospectively predict and monitor the cardiovascular artery diseases. Diagnos' AI will automatically grade the retinal
microcirculation state to generate this score. At regular interval, we will monitor the patients using the same test" said
Dr Hadi Chakor, Diagnos Chief Medical Officer. "Our test will precede painful and stressing invasive procedure that may cause
costly late complication."
While coronary angiography remains the gold standard to confirm the presence and severity of coronary atherosclerosis, issues
of accessibility and cost-effectiveness of the procedure have spurred the need to investigate novel imaging modalities. Diagnos'
Cardio prevention test is based on existing studies (Atherosclerosis Risk in Communities Study ''ARIC'' (Circulation 2016), The
Rotterdam Study (Neurology. 2006), The Beaver Dam Eye Study. (Ophthalmology, 2012), multi-ethnic study of atherosclerosis
(Hypertension, 2008) et al…) that have demonstrated an anatomical correlation between the coronary macro-vascular supply and the
micro-vascular blood supply to the retina. Theses anomalies are strongly associated with cardiovascular risk factors such:
as dyslipidemia, diabetes, smoking hypertension and a positive family history of premature CAD.
We are expecting to complete this final step of test development process during the next 6 months. In using our CARA
telemedicine platform, we've shorten our go to market timeline by 12 months.
"Our test will address one of the more pressing needs in cardiology and preventive medicine field to decrease the
socioeconomic burden and complication cost of this pathology. This approach should complement public actions to reduce community
risk factor levels and promote a healthy lifestyle. The simplicity and costly effectiveness makes this score test with very
promising future to predict cardiovascular disease. The market size and cost associated with CVD & stroke yearly is $386
billions per year (Heidenreich, et al., 2012." said André Larente, CEO, Diagnos.
About CARA
CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the
point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral
to a specialist. CARA's Artificial Intelligence, based on FL AI RE technology,
image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over
the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA
is a cost-effective tool for screening large numbers of patients, in real time and has been approved by regulatory authorities
including Health Canada, US Food and Drug Administration, the European Union and others.
Additional information is available at www.diagnos.ca and www.sedar.com.
This news release contains forward-looking information. There can be no assurance that forward-looking information will
prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements.
DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result
of new information, future events or otherwise. The forward-looking information contained in this news release are expressly
qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.